Cellectar plans phase 3 trial for WM treatment after BTKi

Key facts

• Cellectar plans a phase 3 trial for its Waldenstrom's macroglobulinemia treatment.
• The trial will follow the use of BTKi.
• The pivotal trial is expected to initiate in the second half of 2024.

Waldenstrom's macroglobulinemia (WM) is a rare type of non-Hodgkin lymphoma. Bruton's tyrosine kinase inhibitors (BTKi) are a class of drugs used in treating certain B-cell cancers. This trial represents a significant step in the development of Cellectar's treatment for WM.